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BRCA2 و BRCA1 سري عمل التحري التشخيصي لطفرات جينات
�ضتيل الي، كلري بروكز، ديربا اأو برو�ضري، �ضوان–�ضينج الن، اليني دوهريتي ودوناالد ر. لوف
abstract: Objectives: Screening for mutations in large genes is challenging in a molecular diagnostic 
environment. Sanger-based DNA sequencing methods are largely used; however, massively parallel sequencing 
(MPS) can accommodate increasing test demands and financial constraints. This study aimed to establish a simple 
workflow to amplify and screen all coding regions of the BRCA1 and BRCA2 (BRCA1/2) genes by Sanger-based 
sequencing as well as to assess a MPS approach encompassing multiplex polymerase chain reaction (PCR) and 
pyrosequencing. Methods: This study was conducted between July 2011 and April 2013. A total of 20 patients were 
included in the study who had been referred to Genetic Health Services New Zealand (Northern Hub) for BRCA1/2 
mutation screening. Patients were randomly divided into a MPS evaluation and validation cohort (n = 10 patients 
each). Primers were designed to amplify all coding exons of BRCA1/2 (28 and 42 primer pairs, respectively). Primers 
overlying known variants were avoided to circumvent allelic drop-out. The MPS approach necessitated utilisation of 
a complementary fragment analysis assay to eliminate apparent false-positives at homopolymeric regions. Variants 
were filtered on the basis of their frequency and sequence depth. Results: Sanger-based sequencing of PCR-
amplified coding regions was successfully achieved. Sensitivity and specificity of the combined MPS/homopolymer 
protocol was determined to be 100% and 99.5%, respectively. Conclusion: In comparison to traditional Sanger-
based sequencing, the MPS workflow led to a reduction in both cost and analysis time for BRCA1/2 screening. 
MPS analysis achieved high analytical sensitivity and specificity, but required complementary fragment analysis 
combined with Sanger-based sequencing confirmation in some instances.
Keywords: Massively Parallel Sequencing; BRCA1 Gene; BRCA2 Gene; HBOC Syndrome; Detection, heterozygote.
امللخ�ص: الهدف: ي�ضعب يف بيئة الت�ضخي�س اجلزيئي حتري الطفرات يف اجلينات الكبرية. وعادة ما يقا�س ت�ضل�ضل احلم�س النووي بطرق 
�ضانقر. غري اأن طرق الت�ضل�ضل املوازي وا�ضع النطاق )MPS( ميكنها ا�ضتيعاب الطلب املتزايد من القيا�ضات حتت ظروف قيود مالية كبرية. 
تهدف هذه الدرا�ضة اإىل تقدمي خطة �ضري عمل ت�ضخيم وحتري كل مناطق ال�ضفرات يف جينات BRCA1 و BRCA2 بوا�ضطة طريقة �ضانقر 
 2011 أجريت هذه الدرا�ضة بني يوليو  الطريقة:  )PCR( و�ضل�ضلة البايرو.  MPS التي ت�ضمل تفاعل البلمرة املت�ضل�ضل  وكذلك تقييم طريقة 
 .BRCA1/2 واأبريل 2013، و�ضملت 20 مري�ضا مت حتويلهم اإىل اخلدمات ال�ضحية الوراثية يف نيوزلندا )املحور ال�ضمايل( لتحري طفرات
ومت تق�ضيم املر�ضى ع�ضوائيا لق�ضمني مت�ضاويني، ق�ضم لتقييم طرق الـ MPS، وق�ضم لتوثيق املصداقية. ومت حتديد مناطق بدء العمل لت�ضخيم 
�ضفرة كل اك�ضونات )حموارات( جينات BRCA1 و BRCA2 )28 و 42 زوجا من مناطق بدء العمل، على التوايل(. ومت حتا�ضي مناطق 
العمل التي تعلو املتغريات املعروفة للروغان من اال�ضقاط االأليلي. وتطلب ا�ضتخدام طرق الـ MPS ا�ضتعمال مقاي�ضة مكملة لتحليل ال�ضدفة 
حتى ميكن التخل�س من النتائج االإيجابية الكاذبة الظاهرية حول املناطق البلومرية املتماثلة. ومت تر�ضيح )فلرتة( املتغريات بناء على 
تواترها وت�ضل�ضل عمقها. النتائج: مت بنجاح قيا�س ال�ضفرات بوا�ضطة تسلسل احلم�س النووي امل�ضخم بوا�ضطة الـ PCR واملبني على طريقة 
�ضانقر. وبلغت نسبتا احل�ضا�ضية والنوعية لطريقة MPS %100 و %99.5، على التوايل. اخلال�صة: عند املقارنة مع طريقة �ضانقر التقليدية 
لقيا�س الت�ضل�ضل جند اأن باإمكان �ضري عمل الـ MPS اأن يقلل تكلفة التحري الت�ضخي�ضي لـ BRCA1/2 ويخت�رض من زمنه. وميتاز حتليل 
الـ MPS بن�ضبة عالية من احل�ضا�ضية والنوعية، اإال اأنه يتطلب يف بع�س احلاالت ا�ضتخدام مقاي�ضة مكملة لتحليل ال�ضدفة اإ�ضافة اإىل التثبت 
بوا�ضطة الت�ضل�ضل املبني على طريقة �ضانقر.
مفتاح الكلمات: طرق الت�ضل�ضل املوازي وا�ضع النطاق؛ جني BRCA1؛ جني BRCA2؛ متلزمة HBOC؛ اكت�ضاف، زيجوت متغرية االأالئل.
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Advances in Knowledge
- The research described in this study allows for capillary-based sequencing as well as massively parallel sequencing (MPS) of the BRCA1 
and BRCA2 (BRCA1/2) genes for disease-causing mutations in patients with apparent hereditary breast and ovarian cancer. 
- The results of this study have determined parameters for assessing sequence quality in order to reduce the number of false-positive calls 
using MPS and a pyrosequencing platform.
Application to Patient Care
- The use of MPS enables sequence-detectable mutations to be identified quickly, which is a significant advantage to all patients, regardless 
of their results.
- Furthermore, the MPS approach used in the current study was found to improve turn-around time for screening BRCA1/2 genes and 
reduce the cost of diagnostic screening.
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Conventional Sanger dideoxynucleo-tide (ddNTP) DNA sequencing is the most commonly used method of routine mutation 
screening.1–3 This method was developed in the 1970s 
and has become the gold standard for diagnostic 
sequencing.1,4 However, the cost of Sanger-based 
sequencing is relatively high and the procedure is 
time-consuming, making it impractical for screening 
large genes such as BRCA1 and BRCA2 (BRCA1/2).
The increasing demand for diagnostic genetic 
testing in a clinical setting has created the need for 
an alternative technology that can accommodate high 
throughput, while reducing costs and turnaround 
times. The development of massively parallel 
sequencing (MPS), also known as next-generation 
sequencing, enables the sequencing of millions of 
DNA fragments in a single run.5,6 MPS technology 
has been readily adopted in research settings and 
has recently moved into the diagnostic environment; 
however, this has led to issues regarding sequence 
quality parameters and the need for comprehensive 
bioinformatic analysis. 
In New Zealand, breast cancer is the most 
frequently registered cancer and the second leading 
cause of cancer-related deaths among women. 
Compared to the second half of last century, the 
incidence of breast cancer has increased in New 
Zealand.7 Germline mutations in the BRCA1/2 genes 
account for approximately 10–15% of all breast and 
ovarian cancers; these are known as hereditary breast 
and ovarian cancers (HBOC).8,9 The BRCA1/2 genes, 
which were identified by positional cloning during 
the 1990s, encode for proteins that are responsible for 
controlling cellular growth and differentiation.8
The majority of germline mutations in the BRCA1/2 
genes are either nonsense or frame-shift mutations, 
which result in truncated proteins.8,9 Exonic deletions 
or duplications have also been reported but are rare. 
In view of the above, together with the large number 
of reported mutations, screening the coding regions of 
the BRCA1/2 genes for mutations has largely involved 
denaturing high-performance liquid chromatography 
or direct sequencing.10–14 In contrast, targeted mutation 
analysis using conventional Sanger-based sequencing 
is a common initial testing strategy for individuals 
of Ashkenazi Jewish ancestry with HBOC. Three 
founder mutations have been described in this 
population: c.68_69delAG and c.5266dupC in the 
BRCA1 gene and c.5946delT in the BRCA2 gene, with 
a combined frequency of approximately 2%.15,16 The 
BRCA1/2 genes are classic examples of the difficulties 
commonly encountered in a diagnostic setting: they 
are large autosomal genes with a wide spectrum of 
mutations, rich in homopolymeric regions and are 
highly polymorphic, complicating primer designs for 
polymerase chain reaction (PCR) amplification.17
The objective of this study was to investigate the 
diagnostic potential of the more cost-effective MPS 
approach in screening for mutations in the BRCA1/2 
genes, compared to conventional Sanger-based 
sequencing. This strategy involved a pyrosequencing 
approach in order to develop a rapid, inexpensive 
and rigorous assay for identifying disease-causing 
mutations in the BRCA1/2 genes. 
Methods
This study was carried out between July and April 
2013. A total of 20 patients who had been referred to 
Genetic Health Services New Zealand (Northern Hub) 
for BRCA1/2 gene mutation screening were selected for 
inclusion. Of the patients, 16 carried known disease-
causing mutations. These patients carried a range of 
BRCA1/2 gene variants, including missense, nonsense, 
duplication, insertion-deletion and deletion variants. 
The analysis of whole exon deletion events was excluded 
from the current study as it concerned only the ability 
to detect intra-exonic and splice site mutations.
A total of 10 patients were randomly assigned 
to comprise the MPS evaluation cohort. Genomic 
DNA from the evaluation group was subjected to 
two sequencing strategies. The first comprised exon-
targeted amplification and subsequent Sanger-based 
sequencing of the coding regions of BRCA1/2 while 
the second comprised the MPS approach described 
below. A comparison of the latter data against the 
former allowed MPS analysis parameters to be 
determined. Identified parameters were then applied 
to the genomic DNA of the 10 patients in the MPS 
validation cohort in order to identify sequence variants. 
Variants were identified using SeqNext, Sequence Pilot 
software, Version 3.4.2 (JSI Medical Systems GmbH, 
Kippenheim, Germany). All identified variants, as well 
as amplicons with insufficient coverage (set at 30x 
coverage), were subjected to Sanger-based sequencing 
to determine the sensitivity and specificity of the MPS 
approach. A fragment analysis approach was also used 
in conjunction with MPS to reduce the frequency of 
the false-positive (FP) calls that required Sanger-based 
sequencing confirmation. 
DNA was extracted from peripheral ethylene-
diaminetetraacetic acid (EDTA) blood samples 
using the Gentra® Puregene® Blood Kit (3 mL) 
(Qiagen, Venlo, Limburg, Netherlands), according 
to the manufacturer’s instructions. These DNA 
samples were assessed by an accredited overseas 
laboratory to validate the local gene screening strategy 
used in the study. 
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In order to offer local BRCA1/2 gene screening, 
primers were designed for the simple amplification of 
all coding regions of the two genes. The design process 
used, which allows for amplification using a standard 
reaction condition and cycling protocol, has been 
previously described.18 Critically, the primer designs 
involved extensive analysis of the Single Nucleotide 
Polymorphism Database (dbSNP)19 and an iterative 
design process in order to ensure that primers did 
not overlie known single nucleotide polymorphisms 
(SNPs) using SNPCheck (National Genetics Reference 
Laboratory, Manchester, UK).20 In the case of Sanger-
based sequencing, 70 pairs of primers were designed 
to flank all of the coding and adjacent splice junction 
regions of the BRCA1/2 genes for PCR amplification 
[Appendix 1].21,22 In total, 140 fragments were 
generated with amplicon lengths of 218–745 base 
pairs (bp). The amplicon lengths were short enough 
to allow complete bi-directional sequencing of the 
coding regions of the BRCA1/2 genes. In order to 
allow the unambiguous sequencing of amplicons 
containing repetitive sequences, eight nested primers 
were also designed [Appendix 2].
The coding regions of the BRCA1/2 genes 
were then amplified in a reaction volume of 25 μL 
containing 50 ng of genomic DNA, 0.4 mM of ddNTP 
(GE Healthcare Ltd., Little Chalfont, UK), 0.8 μM each 
of forward and reverse primers, 2 mM of magnesium 
chloride (MgCl2) and one unit of PCR reaction buffer 
without MgCl2 together with one unit of FastStart Taq 
DNA Polymerase (Roche Applied Science, Penzberg, 
Upper Bavaria, Germany). The thermal cycling 
conditions consisted of a denaturation step of 95 °C for 
five minutes, 35 cycles of 94 °C for 45 seconds, 60 °C 
for 30 seconds and 72 °C for 30 seconds, followed by a 
final extension of 72 °C for 10 minutes. Purification of 
each 5 μL of PCR product was performed using USB® 
ExoSAP-IT® (Affymetrix Inc., Santa Clara, California, 
USA). The purified PCR product was then diluted 
to 2.5 ng per 100 bp and sequenced bi-directionally 
using M13 forward and reverse primers and BigDye® 
Terminator Version 3.1 Cycle Sequencing Kit (Applied 
Biosystems, Life Technologies, Thermo Fisher 
Scientific Corp., Carlsbad, California, USA). Sequenced 
products (5 μL) were purified using the BigDye® 
XTerminator™ Purification Kit (Applied Biosystems) 
and then subjected to capillary electrophoresis using 
a 3130xl Genetic Analyser (Applied Biosystems) with 
a 50 cm capillary array. Sequence traces were analysed 
using KB™ Basecaller Sequencing Analysis Software, 
Version 1.4, and Variant Reporter™ Software, Version 
1.0 (Applied Biosystems), with a minimum trace score 
of 35, which corresponds to an average FP base call 
frequency of 0.031%.
MPS library amplification involved the 
amplification of the coding regions of the BRCA1/2 
genes using the BRCA MASTR™ Dx assay 
(Multiplicom, Niel, Belgium) in a reaction volume 
of 15 μL containing 50 ng of genomic DNA. This 
molecular diagnostic assay allows for multiplex PCR 
amplification of 93 amplicons in five separate PCRs for 
each patient. The thermal cycling conditions consisted 
of a denaturation step of 95 °C for 10 seconds, 20 
cycles consisting of 95 °C for 45 seconds, 60 °C for 45 
seconds and 68 °C for two minutes, followed by a final 
extension of 72 °C for 10 minutes. 
Secondary PCR used the 454 MID Dx kit 
(Multiplicom) to tag the amplicons with patient-
specific molecular barcodes and 454 sequencing 
adaptors (A and B) for downstream sequencing. 
The multiplex identifier (MID) sequences consist of 
six unique nucleotides and are used to index each 
BRCA library, allowing multiple patient libraries 
to be multiplexed in a single MPS run. The primary 
PCR products were diluted in sterile water (1:1000) 
and 1 μL of this product was used as a template 
for the secondary PCR with indexing adapters 
in a total reaction volume of 25 μL. The thermal 
cycling conditions consisted of a denaturation step at 
98 °C for 10 seconds, 20 cycles consisting of 95 °C 
for 45 seconds, 64 °C for 45 seconds and 68 °C for 
two minutes, followed by a final extension of 72 °C for 
10 minutes. 
Subsequent pooling of tagged amplicons for 
each patient was followed using a predefined mixing 
protocol (Multiplicom). Each patient’s amplicon-
pooled library was purified using Agencourt AMPure 
XP (Beckman Coulter Inc., Beverly, Massachusetts, 
USA) to remove small residual DNA fragments such 
as primer dimers. The concentration of each patient’s 
amplicon-pooled library was determined using Quant-
iT™ PicoGreen® dsDNA Reagent and Assay Kit (Invit-
rogen, Life Technologies) and normalised to 10 nM 
in Tris-EDTA buffer (pH 8). In each experiment, five 
patients’ amplicon-pooled libraries were pooled in an 
equimolar ratio to generate a sequencing library, which 
contained a total of 465 amplicons for sequencing on 
the MPS platform.
Emulsion PCR using the GS Junior Titanium 
emPCR Lib-A Kit (Roche Diagnostics Corp., Indian-
apolis, Indiana, USA) was performed to clonally 
amplify single DNA molecules in their own micro-
reactors. This was achieved by hybridising the DNA 
library onto primer-coated beads together with 
emulsification through vigorous shaking of an oil-
water mixture and amplification reagents to achieve 
emulsion micro-reactors. After subsequent PCR 
amplification, the micro-reactors were broken and 
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DNA-positive beads were deposited onto a picotiter 
plate for subsequent pyrosequencing. 
Data processing was carried out using a 
predefined amplicon pipeline program, Genome 
Sequencer Run Processor (Roche Applied Science). 
Sequence data were aligned against the reference 
sequences NC_000017.10 (NM_007294.3; BRCA1) 
and NC_000013.10 (NM_000059.3; BRCA2) from 
the Human Genome Assembly (HG19; Genome 
Bioinformatics Group, University of California Santa 
Cruz, USA). Nomenclature from the Human Genome 
Variation Society (HGVS), Version 2.0,23 was used 
to describe all variants with nucleotide numbering 
starting from the first nucleotide of the translated 
sequence. Amplicons with flanking regions of 3–20 bp 
upstream and downstream were analysed using 
SeqNext. Settings were customised to achieve a 
Phred quality score equivalent to 33, as described in 
others studies.24–26 SeqNext sorts the sequence data 
for each patient according to the attached MID and 
variant calling is achieved based on a defined variant 
frequency, which was set at 20%. As pyrosequencing 
errors commonly arise in homopolymeric regions, a 
secondary threshold for these regions of 35% was set 
to filter out apparent FPs. Currently, a minimum read 
depth of 20x is widely adopted in research settings 
as not all targeted regions are evenly sequenced by 
MPS.25,27,28 This threshold, termed the minimum 
base coverage threshold, is necessary in order to 
avoid possible variant miscalling.29 The minimum 
base coverage threshold was set at 30x (combined 
forward and reverse reads) [Table 1]. An initial 
variant frequency (VF) of 20% allowed reliable 
variant calling. Subsequent VF ranges of 40–60% and 
90–100% were used for calling heterozygotes and 
homozygotes, respectively.
BRCA1/2 genes are homopolymer (HP)-rich 
and sequencing homopolymeric regions is a known 
limitation of pyrosequencing technology which can 
hamper its effective use.24,30,31 For this reason, a 
commercially available fragment analysis assay was 
used (BRCA HP kit, Version 2.0, Multiplicom) to 
screen for variants in targeted homopolymeric 
regions in the BRCA1/2 genes. A fragment analysis 
approach was used in conjunction with MPS to reduce 
the frequency of the FP calls that required Sanger-
based sequencing confirmation. This assay targets 29 
homopolymeric regions (stretches of 6 bp or more) 
within the coding regions of the BRCA1/2 genes. Two 
multiplex PCRs were set up in reaction volumes of 
15 μL containing 30 ng of genomic DNA. The thermal 
cycling conditions consisted of a denaturation step at 
98 °C for 10 minutes, 24 cycles consisting of 95 °C for 
45 seconds, 60 °C for 45 seconds and 68 °C for two 
minutes, followed by a final extension of 72 °C for 
10 minutes. The PCR products were electrophoresed 
in the 3130xl Genetic Analyzer and the data were 
analysed using MAQ-S software, Version 1.4.0 
(Multiplicom).
Three strategies were established to reduce the 
number of FP calls. First, MPS using a pyrosequencing 
approach required a complementary strategy to screen 
homopolymeric regions. Regions not covered by the 
fragment analysis assay were therefore subjected to 
Sanger-based sequencing. Second, literature searches 
and bioinformatic splice site analyses using the Berkeley 
Drosophila Genome Project Program (BDGP)32,33 
were used in the case of intronic single base insertions 
or deletions occurring in homopoly-meric tracts of 
≥6 bp or outside of ±3 bp of the exon-intron 
boundaries. These putative variants would be filtered 
out if they were determined highly unlikely to be of 
pathogenic significance, as reporting them would be 
of no clinical significance. Third, it was decided not to 
report variants in the following untranslated regions 
(UTRs) of the BRCA2 gene: c.-26G>A (5’ UTR) and 
c.*105A>C (3’ UTR). While these variants are listed in 
the Breast Cancer Information Core (BIC) database,34 
they have no known clinical significance and thus fall 
outside the regions of interest (ROI) of the current 
study. These exclusion strategies were applied to the 
MPS analysis of the validation cohort.
All patients gave informed consent to be included 
in this study.
Results
Sanger-based sequencing was applied to the evaluation 
cohort (n = 10) who carried a range of BRCA1/2 gene 
variants, including missense, nonsense, insertion-
deletion and deletion variants. Table 2 summarises 
the variants that were detected. External laboratory 
Table 1: Custom settings applied to SeqNext, Sequence 
Pilot Software, Version 3.4.2 (JSI Medical Systems 
GmbH, Kippenheim, Germany) to identify sequence 
variants in the genomic DNA of 10 patients
Setting Parameter
Analyse/ignore region: minimum absolute 
coverage
Off
Low coverage warning 30
Mutations: minimum absolute coverage Off
Mutations: minimum % coverage 20% per 
direction
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reports on the same DNA samples confirmed the 
mutations reported. 
In total, 128 variants were identified, of which 80 
variants were true-positives (TPs) and 48 variants 
were apparent FPs. The latter were identified by 
comparing the variant calls against the Sanger-based 
sequencing data. Of these 48 apparent FPs, 43 lay 
in homopolymeric regions. Of the 43 apparent FP 
variants in homopolymeric regions, 17 were in exons 
(13 were covered by the BRCA HP kit and four lay 
in homoploymeric tracts of five bases only) and 26 
were in introns. Of the remaining five apparent FPs, 
three corresponded to the same intronic deletion of 
one base in a homopolymeric tract that was three 
bases upstream of a splice acceptor site and two were 
sequenced at insufficient read depth. 
Table 2: Variants detected in the BRCA1 and BRCA2 genes of 20 patients using Sanger-based sequencing
Nucleotide Codon Type Patient
1 2 3 4 5 6 7 8 9 10
BRCA1
c.140G>A p.Cys47Tyr M Het*
c.1067A>G p.Gln356Arg M Het Het Het
c.1175_1214del40 p.Leu392Glnfs*5 F Het*
c.2077G>A p.Asp693Asn M Het
c.2082C>T p.Ser694Ser S Het Het Het Hom Hom
c.2311T>C p.Leu771Leu S Het Het Het Hom Hom
c.2315T>C p.Val772Ala M Het
c.2612C>T p.Pro871Leu M Het Het Het Hom Hom
c.3113A>G p.Glu1038Gly M Het Het Het Hom Hom
c.3548A>G p.Lys1183Arg M Het Het Het Hom Hom
c.3756_3759delGTCT p.Ser1253Argfs*10 F Het*
c.4065_4068delTCAA p.Asn1355Lysfs*10 F Het*
c.4308T>C p.Ser1436Ser S Het Het Het Hom Hom
c.4837A>G p.Ser1613Gly M Het Het Het Hom Hom
BRCA2
c.68-7T>A - I Het
c.865A>C p.Asn289His M Het
c.1114A>C p.Asn372His M Het Het Het Hom Het Het Het
c.1365A>G p.Ser455Ser S Het
c.1395A>C p.Val465Val S Het
c.2229T>C p.His743His S Het
c.2971A>G p.Asn991Asp M Het
c.3396A>G p.Lys1132Lys S Het Het Het Het
c.3807T>C p.Val1269Val S Het Het Het
c.7242A>G p.Ser2414Ser S Het Het Het Het
c.7655_7658delTTAA p.Ile2552Thrfs*95 F Het*
c.7762_7764delATAinsTT p.Ile2588Phefs*60 F Het*
c.7806-14T>C - I Het Het Hom Het Het Het Het Hom
c.8297delC p.Thr2766Asnfs*11 F Het*
c.8575delC p.Gln2859Lysfs*4 F Het*
M = missense; Het = heterozygote; Het* = heterozygote disease-causing mutation; FS = frame-shift; S = synonymous; Hom = homozygous; I = intronic.
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The MPS analysis parameters and the exclusion 
strategies derived from the evaluation cohort were 
applied to the MPS analysis of the validation cohort 
(n = 10). A total of 115 variants were identified using 
the MPS analysis parameters; however, 66 calls 
remained after applying the exclusion strategies. 
Sanger sequencing confirmed 62 of these 66 calls to 
be TPs. The remaining four calls were localised to 
homopolymeric regions not covered by the fragment 
analysis assay. Importantly, two pathogenic mutations 
in the BRCA2 gene (c.1813dupA and c.2957dupA) 
were not detected by MPS analysis. These mutations 
occurred in the homopolymeric regions comprising 
eight and seven adenosines, respectively. However, 
these two duplications were clearly identified using 
the fragment analysis assay and MAQ-S software 
[Figures 1A & B]. The sensitivity and specificity of the 
combined MPS/HP protocol was determined to be 
100% and 99.5%, respectively. 
Combining the results of the two cohorts, there 
were 17 true mutations, 11 FPs that were not filtered 
out using the exclusion criteria, four with a VF out 
of the acceptable range and two with insufficient 
base coverage of less than 30 reads. As two of these 
confirmations occurred in the same amplicon of one 
patient, a total of 33 amplicons required sequencing 
confirmation. A summary of the variants detected 
in all 20 patients is presented in Appendix 3, 
together with conclusions regarding their pathogenic 
status based on the BIC database and the Human 
Genome Mutation Database (BIOBASE HGMD® 
Professional, BIOBASE Biological Databases, Beverly, 
Massachusetts, USA).23,34,35 Overall, the sequence data 
showed variations of approximately 10,000–26,700 
total read counts per patient. In terms of read counts 
per amplicon, the variation was 30–1,900. The Sanger-
based sequencing approach achieved a Phred score of 
35 with a base call accuracy of 99.97%.
The MPS/HP mutation screening strategy for 
BRCA1/2 genes resulted in significant savings in terms 
of both the cost of consumables and time by three-fold 
and two-fold, respectively [Appendix 4].
Discussion
In this study, a simple workflow was established using 
a benchtop MPS platform to perform comprehensive 
mutation screening of the BRCA1/2 genes [Figure 2]. 
The MPS analysis achieved high analytical sensitivity 
and specificity, but required complementary fragment 
analysis combined with Sanger-based sequencing 
confirmation in some instances. This complementary 
approach eliminated some of the concerns about the 
inherent limitations of pyrosequencing technology. 
The MPS/HP mutation screening strategy for 
BRCA1/2 genes resulted in significant savings in 
terms of both the cost of consumables and time. 
These advantages are important criteria for diagnostic 
laboratories.36 An added advantage of this study was 
the identification of all variants within the ROI, which 
comprised the coding regions and flanking 20 bp of 
the BRCA1/2 genes.
 
Figure 1 Panel A & B: Fragment analysis of homopolymeric regions. A: Electropherograms of selected fragments 
amplified using a commercially available fragment analysis assay. Heterozygotes are identified by arrows. B: Sequence 
electropherograms of the heterozygous regions of the BRCA1 and BRCA2 genes shown in panel A. The arrows indicate 
that length heterozygosity is due to a differing number of adenosines.
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The quality of sequencing data is the major concern 
when implementing MPS in a diagnostic setting. The 
Phred score system has been widely adopted as a quality 
measure for automated sequencing approaches.24 
Phred scores of 20 for bi-directional sequence data and 
30 for uni-directional data have been recommended 
as rigorous quality control parameters.37 The Sanger-
based sequencing approach utilised had a Phred score 
of 35 and a 99.97% base call accuracy; it is crucial for 
a diagnostic laboratory to maintain this score quality 
when implementing MPS. In order to achieve a similar 
MPS Phred score, a depth of coverage of 30x and a 
VF of 20% were implemented. These measures were 
chosen based on the results of the evaluation cohort 
and the findings of De Leeneer et al.25 
Also referred to as the allelic fraction, VF is the 
proportion of individual reads containing the variant 
call.25 A VF of 100% for homozygotes and 50% for 
heterozygotes is ideal. However, cut-off frequencies 
for heterozygous and homozygous calls have been 
reported from 23–74% and 78–100%, respectively.25 
According to Jones et al., variant calls of <85% for 
homozygous variants and <40% for heterozygous 
variants should be discarded.38 From the MPS data 
in the current study, a homozygous variant with a 
VF of 81% was observed; Sanger-based sequencing 
determined that this variant was a true heterozygote. 
Based on Jones et al.’s findings, a false-negative result 
would have been generated if this call was discarded.38 
As a result, cut-off ranges were defined as 90–100% 
and 40–60% for homozygotes and heterozygotes, 
respectively. Genotypes of variants that fell outside 
of the stated thresholds were confirmed by Sanger- 
based sequencing.
In the current study, a total of 33 amplicons req-
uired sequencing confirmation. However, this sequence 
load reflects samples that were biased towards positive 
mutations. In the case of a mutation-negative patient, 
a Sanger-based sequence load of approximately one 
amplicon would be expected, which would include 
the confirmation of any non-pathogenic or missense 
variants with unknown clinical significance detected 
for the first time.
The ability to multiplex samples is one of the 
main advantages of MPS, allowing for cost-effective 
sequencing with a high sample throughput. The 
current study was largely confined to analysing five 
patients per single experiment. An experiment where 
seven samples were multiplexed was performed to 
improve cost savings; however, both sensitivity and 
specificity decreased with less than 10,000 reads 
generated for each sample. This is lower than the 
manufacturer’s recommendation of 11,000 reads per 
sample. In addition, the average base coverage was 
106 ± 58 bp, which indicated that multiplexing seven 
samples decreased the confidence of variant calls due 
to lower coverage across the ROI.
MPS technology is rapidly evolving and further 
developments and improvements will continue to 
reduce costs. While the current study has presented 
an introduction to MPS in the context of a small 
diagnostic laboratory, the possibility of whole exome 
sequencing and even whole genome sequencing is 
attractive, albeit requiring a significant increase in data 
storage and processing. However, these developments 
suggest that screening a defined number of genes 
in a targeted approach, as shown in this study, will 
be superseded by filtering sequence data to identify 
variants in a defined gene list that is relevant to the 
clinical referral.
The validation of the approach described here 
was limited in scope due to the number of patients 
analysed; hence, the current study could be considered 
under-powered.39 In order to mitigate this feature, 
further work has been undertaken assessing an 
additional 70 patients referred for BRCA1/2 gene 
sequencing by MPS. These data (not shown here) 
comprise the identification of approximately 500 
variants, all of which are either known exonic and 
intronic SNPs (averaging seven per patient), known 
mutations (eight patients) or novel mutations (two 
patients). All mutations were confirmed as correct 
by Sanger-based sequencing. Importantly, the exon-
specific primer designs have provided a critical 
resource for the confirmation of variants detected 
by MPS and for predictive testing. The fact that the 
 
Figure 2: Flowchart of massively parallel sequencing/
homopolymer workflow for BRCA1 and BRCA2 referrals.
MPS = massively parallel sequencing; HP = homopolymer; VF = 
variant frequency; FP = false-positive; UTR = untranslated region.  
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primers do not overlie known SNPs has reduced the 
likelihood of allelic drop-out.
Conclusion
In comparison to traditional Sanger-based sequencing, 
the MPS workflow led to a reduction in cost, analysis 
time and turn-around time for the screening of 
BRCA1/2 genes. The analysis used achieved high 
analytical sensitivity and specificity, but required 
complementary fragment analysis combined with 
Sanger-based sequencing confirmation in some 
instances. MPS technology is rapidly evolving 
and further developments and improvements will 
continue to reduce costs. The current study presented 
an introduction to MPS in the context of a small 
diagnostic laboratory.
appendices
Primer sequences, nested primers for sequencing 
selected exons, BRCA1/2 gene variants detected and 
a brief cost-efficiency analysis of the methods used are 
available in four supplementary tables included in the 
online version of this article.
conflict of interest 
The authors declare no conflicts of interest.
References
1. França LT, Carrilho E, Kist TB. A review of DNA sequencing 
techniques. Q Rev Biophys 2002; 35:169–200. doi: 10.1017/
S0033583502003797.
2. Metzker ML. Sequencing technologies: The next generation. 
Nat Rev Genet 2010; 11:31–46. doi: 10.1038/nrg2626.
3. Zhou X, Ren L, Meng Q, Li Y, Yu Y, Yu J. The next-generation 
sequencing technology and application. Protein Cell 2010; 
1:520–36. doi: 10.1007/s13238-010-0065-3. 
4. Sanger F, Nicklen S, Coulson AR. DNA sequencing with 
chain-terminating inhibitors. Proc Natl Acad Sci U S A 1977; 
74:5463–7. doi: 10.1073/pnas.74.12.5463.
5. Wheeler DA, Srinivasan M, Egholm M, Shen Y, Chen L, 
McGuire A, et al. The complete genome of an individual by 
massively parallel DNA sequencing. Nature 2008; 452:872–6. 
doi: 10.1038/nature06884.
6. Voelkerding KV, Dames SA, Durtschi JD. Next-generation 
sequencing: From basic research to diagnostics. Clin Chem 
2009; 55:641–58. doi: 10.1373/clinchem.2008.112789.
7. Cunningham R, Shaw C, Blakely T, Atkinson J, Sarfati D. Ethnic 
and socioeconomic trends in breast cancer incidence in New 
Zealand. BMC Cancer 2010; 10:674. doi: 10.1186/1471-2407-
10-674.
8. Taylor MR. Genetic testing for inherited breast and ovarian 
cancer syndromes: Important concepts for the primary care 
physician. Postgrad Med J 2001; 77:11–15. doi: 10.1136/
pmj.77.903.11.
9. Michils G, Hollants S, Dehaspe L, Van Houdt J, Bidet Y, 
Uhrhammer N, et al. Molecular analysis of the breast cancer 
genes BRCA1 and BRCA2 using amplicon-based massive 
parallel pyrosequencing. J Mol Diagn 2012; 14:623–30. doi: 
10.1016/j.jmoldx.2012.05.006.
10. Kim BY, Lee DG, Lee KR, Han SH, Surendran S, Han CW, et al. 
Identification of BRCA1 and BRCA2 mutations from Korean 
breast cancer patients using denaturing HPLC. Biochem 
Biophys Res Commun 2006; 349:604–10. doi: 10.1016/j.
bbrc.2006.08.086.
11. Ou J, Wu T, Sijmons R, Ni D, Xu W, Upur H. Prevalence of 
BRCA1 and BRCA2 germline mutations in breast cancer 
women of multiple ethnic region in northwest China. J Breast 
Cancer 2013; 16:50–4. doi: 10.4048/jbc.2013.16.1.50.
12. Ratajska M, Brozek I, Senkus-Konefka E, Jassem J, Stepnowska 
M, Palomba G, et al. BRCA1 and BRCA2 point mutations and 
large rearrangements in breast and ovarian cancer families in 
Northern Poland. Oncol Rep 2008; 19:263–8. doi: 10.3892/
or.19.1.263.
13. Riahi A, Kharrat M, Ghourabi ME, Khomsi F, Gamoudi A, 
Lariani I, et al. Mutation spectrum and prevalence of BRCA1 
and BRCA2 genes in patients with familial and early-onset 
breast/ovarian cancer from Tunisia. Clin Genet 2013. doi: 
10.1111/cge.12337. [Epub ahead of print].
14. Vuttariello E, Borra M, Calise C, Mauriello E, Greggi S, 
Vecchione A, et al. A new rapid methodological strategy to 
assess BRCA mutational status. Mol Biotechnol 2013; 54:954–
60. doi: 10.1007/s12033-012-9646-0.
15. Struewing JP, Hartge P, Wacholder S, Baker SM, Berlin M, 
McAdams M, et al. The risk of cancer associated with specific 
mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl 
J Med 1997; 336:1401–8. doi: 10.1056/NEJM199705153362001.
16. Roa BB, Boyd AA, Volcik K, Richards CS. Ashkenazi Jewish 
population frequencies for common mutations in BRCA1 and 
BRCA2. Nat Genet 1996; 14:185–7. doi: 10.1038/ng1096-185.
17. Tarabeux J, Zeitouni B, Moncoutier V, Tenreiro H, Abidallah K, 
Lair S, et al. Streamlined ion torrent PGM-based diagnostics: 
BRCA1 and BRCA2 genes as a model. Eur J Hum Genet 2014; 
22:535–41. doi: 10.1038/ejhg.2013.181.
18.  Doherty E, Marquis-Nicholson R, Love JM, Brookes C, Prosser 
D, Love DR. Primer design to sequence analysis: A pipeline 
for a molecular genetic diagnostic laboratory. In: Ivanov O, 
Ed. Applications and Experiences of Quality Control. Rijeka, 
Croatia: InTech, 2011. Pp. 257–72.
19. National Center for Biotechnology Information. dbSNP. From: 
www.ncbi.nlm.nih.gov/snp  Accessed: Sep 2014.
20. National Genetics Reference Laboratory Manchester. 
SNPCheck. From: www.ngrl.org.uk/Manchester/projects/
snpcheck  Accessed: Sep 2014.
21. Messing J. New M13 vectors for cloning. Methods Enzymol 
1983; 101:20–78. doi: 10.1016/0076-6879(83)01005-8.
22. Yanisch-Perron C, Vieira J, Messing J. Improved M13 phage 
cloning vectors and host strains: Nucleotide sequences of the 
M13mp18 and pUC19 vectors. Gene 1985; 33:103–19. doi: 
10.1016/0378-1119(85)90120-9.
23.  Human Genome Variation Society (HGVS). Nomenclature for 
the Description of Sequence Variants. From: www.hgvs.org/
mutnomen  Accessed: Sep 2014.
24. Mardis ER. The impact of next-generation sequencing 
technology on genetics. Trends Genet 2008; 24:133–41. doi: 
10.1016/j.tig.2007.12.007.
25. De Leeneer K, De Schrijver J, Clement L, Baetens M, Lefever 
S, De Keulenaer S, et al. Practical tools to implement massive 
parallel pyrosequencing of PCR products in next generation 
molecular diagnostics. PLoS One 2011; 6:e25531. doi: 10.1371/
journal.pone.0025531.
Diagnostic Screening Workflow for Mutations in the BRCA1 and BRCA2 Genes
e66 | SQU Medical Journal, February 2015, Volume 15, Issue 1
26.  Ewing B, Green P. Base-calling of automated sequencer traces 
using phred: II - Error probabilities. Genome Res 1998; 8:186–
94. doi: 10.1101/gr.8.3.175.
27. Ellard S, Charlton R, Lindsay H, Camm N, Watson C, Abbs S, 
et al.; Clinical Molecular Genetics Society. Practice guidelines 
for Targeted Next Generation Sequencing Analysis and 
Interpretation. From: www. cmgsweb.shared.hosting.zen.co.uk/
BPGs/BPG%20for%20targeted%20next%20generation%20
sequencing%20final.pdf  Accessed: Feb 2014.
28. Craig DW, Pearson JV, Szelinger S, Sekar A, Redman M, 
Corneveaux JJ, et al. Identification of genetic variants using bar-
coded multiplexed sequencing. Nat Methods 2008; 5:887–93. 
doi: 10.1038/nmeth.1251.
29. Gargis AS, Kalman L, Berry MW, Bick DP, Dimmock DP, 
Hambuch T, et al. Assuring the quality of next-generation 
sequencing in clinical laboratory practice. Nat Biotechnol 2012; 
30:1033–6. doi: 10.1038/nbt.2403.
30. Balzer S, Malde K, Lanzén A, Sharma A, Jonassen I. 
Characteristics of 454 pyrosequencing data: Enabling realistic 
simulation with flowsim. Bioinformatics 2010; 26:i420–5. doi: 
10.1093/bioinformatics/btq365.
31. Balzer, S, Malde K, Jonassen I. Systematic exploration of error 
sources in pyrosequencing flowgram data. Bioinformatics 2011; 
27:i304–9. doi: 10.1093/bioinformatics/btr251. 
32. Berkeley Drosophila Genome Project (BDGP). Splice Site 
Prediction by Neural Network. From: www.fruitfly.org/seq_
tools/splice.html  Accessed: Sep 2014.
33. Reese MG, Eeckman FH, Kulp D, Haussler D. Improved splice 
site detection in Genie. J Comput Biol 1997; 4:311–23. doi: 
10.1145/267521.267766.
34. National Human Genome Research Institute, National 
Institutes of Health. Breast Cancer Information Core: An open 
access on-line breast cancer mutation data base. From: www.
research.nhgri.nih.gov/bic/  Accessed: Sep 2014.
35. BIOBASE Biological Databases. HGMD® Human Gene 
Mutation Database. From: www.biobase-international.com/
product/hgmd  Accessed: Sep 2014.
36. Alansari A, Al-Rawahi S, Ba-Omar T, Al-Nabhani M, Date 
A. The identification of Pompe disease mutations in archival 
tissues and development of a rapid molecular-based test. Sultan 
Qaboos Univ Med J 2013; 13:502–9.
37. Ellard S, Charlton R, Lindsay H, Camm N, Watson C, Abbs S, 
et al.; Clinical Molecular Genetics Society. Practice guidelines 
for Targeted Next Generation Sequencing Analysis and 
Interpretation. From: www.cmgsweb.shared.hosting.zen.co.uk/
BPGs/BPG%20for%20targeted%20next%20generation%20
sequencing%20final.pdf  Accessed: Feb 2014.
38. Jones MA, Bhide S, Chin E, Ng BG, Rhodenizer D, Zhang VW, 
et al. Targeted polymerase chain reaction-based enrichment 
and next generation sequencing for diagnostic testing of 
congenital disorders of glycosylation. Genet Med 2011; 13:921–
32. doi: 10.1097/GIM.0b013e318226fbf2.
39. Mattocks CJ, Morris MA, Matthijs G, Swinnen E, Corveleyn A, 
Dequeker E, et al. A standardized framework for the validation 
and verification of clinical molecular genetic tests. Eur J Hum 
Genet 2010; 18:1276–88. doi: 10.1038/ejhg.2010.101.
Appendix 1: Primer sequences for amplifying the coding regions of the BRCA1 and BRCA2 genes
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Appendix 2: Nested primers for sequencing selected exons of the BRCA1 and BRCA2 genes
Exon Primer Sequence
BRCA1
6 Internal reverse GAAGAAGAAAACAAATGG
8 Internal forward ACCCTTTTAATTAAGAAA
BRCA2
3 Internal forward GATTTAGGACCAATAAG
9 Internal reverse CAACAACAACAAAAAAACC
10-3 Internal reverse GTACTATTTACAAAAAAAAAAA
13 Internal reverse GGGAAGTGTTAACTTCT
15-1 Internal forward GCTAAGTATTTATTCTTTG
15-1 Internal reverse CCATCAGTATTGTAGAC
Appendix 3: BRCA1 and BRCA2 gene variants* detected in 20 DNA samples










c.140G>A p.Cys47Tyr Missense DM - MPS 1
c.212+1G>T Intronic IVS DM Yes MPS 1
c.213-11T>G Intronic IVS DM Yes MPS 1
c.1067A>G p.Gln356Arg Missense DP Unknown MPS 3
c.1175_1214del40 p.Leu392GlnfsX5 Frame-shift DM Yes MPS 1
c.2077G>A p.Asp693Asn Missense DP No MPS 2
c.2082C>T p.Ser694Ser Synonymous - Unknown MPS 9
c.2311T>C p.Leu771Leu Synonymous - Unknown MPS 9
c.2315T>C p.Val772Ala Missense DM Unknown MPS 1
c.2612C>T p.Pro871Leu Missense DFP No MPS 8
c.2612delCinsTT p.Pro871LeufsX32 Frame-shift DM - MPS 1
c.3113A>G p.Glu1038Gly Missense DP No MPS 9
c.3119G>A p.Ser1040Asn Missense DM? Unknown MPS 1
c.3548A>G p.Lys1183Arg Missense DP No MPS 9

















Blue = 5’ tails for forward primers taken from the M13 bacteriophage genome. 21,22 Red = 5’ tails for reverse primers taken from the M13 
bacteriophage genome.21,22
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c.3756_3759delGTCT p.Ser1253ArgfsX10 Frame-shift DM Yes MPS 1
c.4065_4068delTCAA p.Asn1355LysfsX10 Frame-shift DM Yes MPS 1
c.4308T>C p.Ser1436Ser Synonymous - Unknown MPS 9
c.4837A>G p.Ser1613Gly Missense DM? No MPS 9
BRCA2
c.68-7T>A Intronic IVS DM Unknown MPS 1
c.865A>C p.Asn289His Missense DP No MPS 1
c.1114A>C p.Asn372His Missense DFP C>A MPS 11
c.1365A>G p.Ser455Ser Synonymous - No MPS 1
c.1395A>C p.Val465Val Synonymous - Unknown MPS 1
c.1813dupA p.Ile605AsnfsX11 Frame-shift DM Yes HP kit 1
c.1938C>T p.Ser646Ser Synonymous - No MPS 1
c.2229T>C p.His743His Synonymous - No MPS 1
c.2957dupA p.Asn986LysfsX2 Frame-shift DM Yes HP kit 1
c.2971A>G p.Asn991Asp Missense DM? No MPS 1
c.3396A>G p.Lys1132Lys Synonymous - No MPS 10
c.3807T>C p.Val1269Val Synonymous - No MPS 5
c.4478_4481delAAAG p.Glu1493ValfsX10 Frame-shift DM Yes MPS 1
c.7242A>G p.Ser2414Ser Synonymous - No MPS 6
c.7655_7658delTTAA p.Ile2552ThrfsX95 Frame-shift DM Yes MPS 1
c.7762_7764delATAinsTT p.Ile2588PhefsX60 Frame-shift DM - MPS 1
c.7806-14T>C Intronic IVS - Unknown MPS 17
c.7977-1G>C Intronic IVS DM Yes MPS 1
c.8149G>T p.Ala2717Ser Missense DM? No MPS 1
c.8297delC p.Thr2766AsnfsX11 Frame-shift DM Yes MPS 1
c.8575delC p.Gln2859LysfsX4 Frame-shift DM Yes MPS 1
c.9257-16T>C Intronic IVS - Unknown MPS 1
c.9976A>T p.Lys3326X Nonsense DP No MPS 1
DM = disease-causing mutation; - = not reported; MPS = massively parallel sequencing; IVS = intervening sequence; DP = disease-associated 
polymorphism; DFP: disease-associated polymorphism with additional supporting functional evidence; DM? = potential disease-causing mutation; 
C>A = reported as base pair change from cytosine to adenine; HP = homopolymer. 
*Variants are named according to Human Genome Variation Society nomenclature, Version 2.0.23 
†According to the Human Genome Mutation Database (BIOBASE HGMD® Professional, BIOBASE Biological Databases, Beverly, Massachusetts, 
USA) in February 2013.35 
‡According to the 2014 Breast Cancer Information Core database.34 
§Number of times the variant was observed in the DNA samples.
Appendix 4: Cost-efficiency of massively parallel sequencing/homopolymer mutation screening strategy for BRCA1 
and BRCA2 genes
Sanger sequencing Multiplexing five samples sequenced by MPS Savings
Cost per sample in NZD 2,700 820 1,880
Time per sample in minutes 510 284 226
NZD = New Zealand Dollars; MPS = massively parallel sequencing.
